Table 2.
Seroprevalence of Campylobacter (using P18, P39 & P18&P39), Helicobacter pylori, Mycoplasma pneumoniae, Yersinia enterocolitica, and Borrelia afzelii in the different patient groups
| Bacterium | Campylobacter OMP18 | Campylobacter P39 | Campylobacter P18 + P39 | Helicobacter pylori | Mycoplasma pneumoniae | Yersinia enterocolitica | Borrelia afzelii | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ig class | IgA | IgG | IgA | IgG | IgA | IgG | IgA | IgG | IgA | IgG | IgA | IgG | IgG | |
| BD | + | 9 % (7/80) | 9 % (7/80) | 9 % (7/80) | 9 % (7/80) | 9 % (7/80) | 9 % (7/80) | 9 % (7/80) | 9 % (7/80) | 9 % (7/80) | 8 % (6/80) | 9 % (7/80) | 9 % (7/80) | 9 % (7/80) |
| ± | 8 % (6/80) | 5 % (4/80) | 4 % (3/80) | 8 % (6/80) | 3 % (2/80) | 5 % (4/80) | 4 % (3/80) | 9 % (7/80) | 1 % (1/80) | 6 % (5/80) | 5 % (4/80) | 1 % (1/80) | 6 % (5/80) | |
| - | 84 % (67/80) | 86 % (69/80) | 88 % (70/80) | 84 % (67/80) | 89 % (71/80) | 86 % (69/80) | 88 % (70/80) | 83 % (66/80) | 90 % (72/80) | 86 % (69/80) | 86 % (69/80) | 90 % (72/80) | 85 % (68/80) | |
| AE | + | 53 %*** (32/60) | 45 %*** (27/60) | 37 %*** (22/60) | 52 %*** (31/60) | 35 %*** (21/60) | 43 %*** (26/60) | 3 %* (2/60) | 2 %* (1/60) | 3 %* (2/60) | 25 %** (15/60) | 37 %*** (22/60) | 15 %* (9/60) | 22 %** (13/60) |
| ± | 7 % (4/60) | 13 % (8/60) | 10 % (6/60) | 10 % (6/60) | 10 % (6/60) | 8 % (5/60) | 7 % (4/60) | 0 % (0/60) | 3 % (2/60) | 5 % (3/60) | 12 % (7/60) | 13 % (8/60) | 8 % (5/60) | |
| - | 40 % (24/60) | 42 % (25/60) | 53 % (32/60) | 38 % (23/60) | 55 % (33/60) | 48 % (29/60) | 90 % (54/60) | 98 % (59/60) | 93 % (56/60) | 70 % (42/60) | 52 % (31/60) | 72 % (43/60) | 70 % (42/60) | |
| GBS | + | 45 %*** (41/91) | 26 %** (24/91) | 35 %*** (32/91) | 37 %*** (34/91) | 48 %*** (44/91) | 37 %*** (34/91) | 19 %** (17/91) | 10 %* (9/91) | 10 %* (9/91) | 21 %* (19/91) | 41 %** (37/91) | 20 %* (18/91) | 38 %*** (35/91) |
| ± | 9 % (8/91) | 15 % (14/91) | 10 % (9/91) | 16 % (15/91) | 7 % (6/91) | 9 % (8/91) | 7 % (6/91) | 13 % (12/91) | 4 % (4/91 %) | 8 % (7/91) | 18 % (16/91) | 11 % (10/91) | 9 % (8/91) | |
| - | 46 % (42/91) | 58 % (53/91) | 55 % (50/91) | 46 % (42/91) | 45 % (41/91) | 54 % (49/91) | 75 % (68/91) | 77 % (70/91) | 86 % (78/91) | 71 % (65/91) | 42 % (38/91) | 69 % (63/91) | 53 % (48/91) | |
| RA | + | 40 %*** (20/50) | 34 %** (17/50) | 26 %** (13/50) | 54 %*** (27/50) | 34 %** (17/50) | 30 %** (15/50) | 8 %* (4/50) | 8 %* (4/50) | 6 %* (3/50) | 36 %*** (18/50) | 30 %** (15/50) | 38 %*** (19/50) | 8 %* (4/50) |
| ± | 8 % (4/50) | 14 % (7/50) | 10 % (5/50) | 12 % (6/50) | 6 % (3/50) | 18 % (9/50) | 2 % (1/50) | 0 % (0/50) | 6 % (3/50) | 8 % (4/50) | 10 % (5/50) | 14 % (7/50) | 12 % (6/50) | |
| - | 52 % (26/50) | 52 % (26/50) | 64 % (32/50) | 34 % (17/50) | 60 % (30/50) | 52 % (26/50) | 90 % (45/50) | 92 % (46/50) | 88 % (44/50) | 56 % (28/50) | 60 % (30/50) | 48 % (24/50) | 80 % (40/50) | |
| IBD | + | 33 %** (13/39) | 18 %* (7/39) | 26 %** (10/39) | 44 %*** (17/39) | 26 %** (10/39) | 23 % * (9/39) | 5 %* (2/39) | 3 %* (1/39) | 5 %* (2/39) | 26 %** (10/39) | 28 %** (11/39) | 21 %* (8/39) | 26 %** (10/39) |
| ± | 5 % (2/39) | 13 % (5/39) | 3 % (1/39) | 3 % (1/39) | 5 % (2/39) | 13 % (5/39) | 18 % (7/39) | 10 % (4/39) | 8 % (3/39) | 8 % (3/39) | 15 % (6/39) | 18 % (7/39) | 3 % (1/39) | |
| - | 62 % (24/39) | 69 % (27/39) | 72 % (28/39) | 54 % (21/39) | 69 % (27/39) | 64 % (25/39) | 77 % (30/39) | 87 % (34/39) | 87 % (34/39) | 67 % (26/39) | 56 % (22/39) | 62 % (24/39) | 72 % (28/39) | |
AE acute campylobacteriosis (reference: stool culture), GBS Guillain-Barré-Syndrome, RA reactive arthritis, IBD inflammatory bowel disease (Morbus Crohn & ulcerative colits); + positive, ± borderline, - negative.
Different significance levels in the comparison of a particular patient group with blood donors (BD) are indicated with ‘*’ (p > 0.05 = not significant), ‘**’ (p < 0.05 = significant), and ‘***’ (p < 0.001 = significant)